PetOncoCare is a cancer diagnostic testing and R&D company established to support veterinarians’ professional diagnosis and tailored treatment for companion animal cancer patients.

As Korea’s only company specialized in companion animal cancer diagnostic testing, founded by veterinarian with expertise in cancer research, we recognize the importance of veterinary oncology and the need for precision medical services, and are continually developing test methods.

PetOncoCare has established an advanced method for in vitro culture of patient-derived tumor cells with the accumulated know-how of the research team, along with development of advanced cancer cell and gene analysis technologies.

We provide a chemotherapy response prediction test, which is a cell-based assay designed to accurately assess chemosensitivity, and also provide target molecule expression and genetic mutation tests.

In addition, PetOncoCare performs liquid biopsy-based genetic testing that can be used forcancer diagnosis and monitoring treatment effect.

We strive to ensure the delivery of reliable test results in the shortest possible time.

We will continue to develop and provide fast and accurate test services required in clinical practice.

CEO of PetOncoCare